Condition: Acute Myeloid Leukaemia · Sponsor: Zhongnan Hospital
Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).
This description comes directly from the study's public registry record.
Fuling Zhou, Doctor · 027-67813137 · zhoufuling@whu.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| The Central Hospital of Huanggang | Huanggang, Hubei, China | Not Yet Recruiting |
| The First People's Hospital of Jingzhou | Jingzhou, Hubei, China | Not Yet Recruiting |
| Jingzhou Central Hospital | Jingzhou, Hubei, China | Not Yet Recruiting |
| Shiyan Taihe Hospital | Shiyan, Hubei, China | Not Yet Recruiting |
| Zhongnan Hospital of Wuhan University | Wuhan, Hubei, China | Recruiting |
| Xianning Central Hospital | Xianning, Hubei, China | Not Yet Recruiting |
| The Central Hospital of Xiaogan | Xiaogan, Hubei, China | Not Yet Recruiting |
| Yichang Central Hospital | Yichang, Hubei, China | Not Yet Recruiting |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Wuxi, Jiangsu, China | Not Yet Recruiting |
| Shanxi Cancer Hospital | Taiyuan, Shanxi, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06345365